Stock Ticker

  • Loading stock data...

Sarepta Therapeutics’ Eteplirsen Study Reveals Benefits to Patients (SRPT)

Sarepta Therapeutics (NASDAQ: SRPT), an RNA-based therapeutics company that develops drugs to treat serious, life-threatening, rare and infectious diseases, announced at the Action Duchenne meeting in London that patients treated with eteplirsen continue to do well. Benefits to Patients Sarepta’s Chief Medical Officer, Dr. Ed Kaye, was speaking about the results from the phase II […]

Sign Up To Get Our Latest Stocks Alerts